Neurocentrx is pioneering what it says will be the first abuse-deterrent oral ketamine prescription, pairing a novel capsule formulation with proprietary digital prescription software to enable a regulated clinic-to-home care pathway. The company targets severe mood disorders, initially treatment-resistant major depressive disorder (TR-MDD) and treatment-resistant bipolar depression (TR-BPD). Its digital platform is designed to bolster patient safety, provider communication and adherence, creating a scalable model for ketamine-based and future therapies. Headquartered in the UK with operations in the US and Australia, Neurocentrx leverages global clinical research expertise. The firm has just secured a seed extension round that delivers over $5 million to advance its clinical programmes. Proceeds will fund a proof-of-concept Phase 2 trial in TR-BPD beginning in Q1 2026. Management is now pursuing a Series A round to finance Phase 2 and Phase 3 trials in TR-MDD, underscoring the capital requirements typical of late-stage psychiatric drug development.

Total raised

$5M

Funding rounds

2

Latest round

Seed

Latest activity

Sep 2025